EMD-49362

Single-particle
2.58 Å
EMD-49362
3D View Gallery
Deposition: 21/02/2025
Map released: 08/10/2025
Last modified: 31/12/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-49362

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9nfc summary report (pdf.gz) Map-9nfc FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Structure of the cross-HLA supertype antibody R302 bound to a class I MHC presenting a divarasib-modified KRAS-G12C peptide on HLA-A*03

EMD-49362

Single-particle
2.58 Å
EMD-49362
3D View Gallery
Deposition: 21/02/2025
Map released: 08/10/2025
Last modified: 31/12/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: Binary complex of Fab R302 with divarasib-conjugated KRAS G12C peptide (7-16) presented by class I MHC having HLA-A*03:01
Fitted models: 9nfc

Deposition Authors: Maso L
Engineered antibodies that stabilize drug-modified KRAS G12C neoantigens enable selective and potent cross-HLA immunotherapy.
Maso L, Mosure SA, Rodriguez-Aponte SA, Pizzo A, Mensah DN, Southard M, Sze S, Ahmed T, Vash B, Hattori T , Rajak E , Koide A , Neel BG , Koide S , Liu W, Toenjes ST, Jardine PDS, Chopra R, Rader C , Stopfer LE
(2025) Nat Commun , 16 , 11264 - 11264
PUBMED: 41408054
DOI: doi:10.1038/s41467-025-66132-w
ISSN: 2041-1723
Grant Support: